Cor pulmonale PAH is considered a universally fatal illness, although survival time may vary between individuals. The prognosis of pulmonary arterial<unk>  (WHO Group I) has an untreated median survival of 2–3 years from time of diagnosis, with the cause of death usually being right ventricular failure (cor pulmonale). The survival time is variable and depends on many factors. A recent outcome study of those patients who had started treatment with bosentan (Tracleer) showed that 89% of patients were alive at 2 years. With new therapies, survival rates are increasing. For 2,635 patients enrolled in The Registry to Evaluate Early and Long-term Pulmonary Arterial<unk>  Disease Management (REVEAL Registry) from March 2006 to December 2009, 1-, 3-, 5-, and 7-year survival rates were 85%, 68%, 57%, and 49%, respectively. For patients with idiopathic/familial PAH, survival rates were 91%, 74%, 65%, and 59%. Levels of mortality are very high in pregnant women with severe pulmonary arterial<unk>  (WHO Group I). Pregnancy is sometimes described as contraindicated in these women.
Pulmonary hypertension
Portopulmonary hypertension
Chronic thromboembolic pulmonary hypertension
Asthma
Chronic obstructive pulmonary disease
Emphysema
Hypertensive heart disease
Reactive airway disease